Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

L. Khoja; P. Lorigan; C. Zhou; M. Lancashire; J. Booth; J. Cummings; R. Califano; G. Clack; A. Hughes; C. Dive

doi:10.1038/jid.2012.468

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

L. Khoja, P. Lorigan, C. Zhou, M. Lancashire, J. Booth, J. Cummings, R. Califano, G. Clack, A. Hughes, C. Dive

Cancer Research UK Manchester Institute

Research output: Contribution to journal › Article › peer-review

Abstract

The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic biomarkers. A total of 101 patients with metastatic cutaneous melanoma were recruited prospectively. CTC number was determined using the CellSearch platform and melanoma kits in samples taken at baseline and serially during treatment. CTC numbers ranged between 0 and 36 per 7.5 ml blood; 26% of patients had ≥ 2 CTCs. Baseline CTC number was prognostic for median overall survival (OS) in univariate analysis (2.6 vs. 7.2 months (P

Original language	English
Pages (from-to)	1582
Number of pages	8
Journal	The Journal of Investigative Dermatology
Volume	133
Issue number	6
DOIs	https://doi.org/10.1038/jid.2012.468
Publication status	Published - 1 Jun 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/jid.2012.468

Cite this

@article{30639cbd6d7c4c3cab1b9543321bf31d,

title = "Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma",

abstract = "The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic biomarkers. A total of 101 patients with metastatic cutaneous melanoma were recruited prospectively. CTC number was determined using the CellSearch platform and melanoma kits in samples taken at baseline and serially during treatment. CTC numbers ranged between 0 and 36 per 7.5 ml blood; 26% of patients had ≥ 2 CTCs. Baseline CTC number was prognostic for median overall survival (OS) in univariate analysis (2.6 vs. 7.2 months (P",

author = "L. Khoja and P. Lorigan and C. Zhou and M. Lancashire and J. Booth and J. Cummings and R. Califano and G. Clack and A. Hughes and C. Dive",

year = "2013",

month = jun,

day = "1",

doi = "10.1038/jid.2012.468",

language = "English",

volume = "133",

pages = "1582",

journal = "The Journal of Investigative Dermatology",

issn = "1523-1747",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

AU - Khoja, L.

AU - Lorigan, P.

AU - Zhou, C.

AU - Lancashire, M.

AU - Booth, J.

AU - Cummings, J.

AU - Califano, R.

AU - Clack, G.

AU - Hughes, A.

AU - Dive, C.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic biomarkers. A total of 101 patients with metastatic cutaneous melanoma were recruited prospectively. CTC number was determined using the CellSearch platform and melanoma kits in samples taken at baseline and serially during treatment. CTC numbers ranged between 0 and 36 per 7.5 ml blood; 26% of patients had ≥ 2 CTCs. Baseline CTC number was prognostic for median overall survival (OS) in univariate analysis (2.6 vs. 7.2 months (P

AB - The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic biomarkers. A total of 101 patients with metastatic cutaneous melanoma were recruited prospectively. CTC number was determined using the CellSearch platform and melanoma kits in samples taken at baseline and serially during treatment. CTC numbers ranged between 0 and 36 per 7.5 ml blood; 26% of patients had ≥ 2 CTCs. Baseline CTC number was prognostic for median overall survival (OS) in univariate analysis (2.6 vs. 7.2 months (P

U2 - 10.1038/jid.2012.468

DO - 10.1038/jid.2012.468

M3 - Article

C2 - 23223143

SN - 1523-1747

VL - 133

SP - 1582

JO - The Journal of Investigative Dermatology

JF - The Journal of Investigative Dermatology

IS - 6

ER -

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this